The term ‘mRNA’ entered the public lexicon in a massive way with the impact of mRNA vaccines during the COVID-19 pandemic. But did you know that the technological advancement of mRNA vaccines had a much-acclaimed predecessor, known as mRNA reprogramming? While mRNA vaccines apply mRNA technology to making vaccines, mRNA reprogramming employs it in the domains of cell biology and cell therapy development.
Allele Biotech is both fortunate and proud to have been one of the two pioneering groups in the realm of mRNA reprogramming, initiating our development back in 2010 and subsequently publishing our method in 2012 (https://www.nature.com/articles/srep00657). We have played a crucial role in enhancing the efficiency and consistency of this technology, ultimately paving the way for its seamless transition into cGMP production. In fact, we are the world’s first to establish a cGMP reprogramming and iPSC expansion facility, since 2018.
Some additional information about Allele Biotech’s cGMP mRNA reprogramming:
For more information, feel free to reach out to us via email at info@allelebiotech.com, and we will be delighted to initiate the conversation from there.